- Home
- BRNS
as 07-05-2024 4:00pm EST
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
| Founded: | 2016 | Country: | United Kingdom |
| Employees: | N/A | City: | DIDCOT |
| Market Cap: | 54.1M | IPO Year: | 2021 |
| Target Price: | $5.50 | AVG Volume (30 days): | 32.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.21 - $5.10 | Next Earning Date: | 08-08-2024 |
| Revenue: | $334,000 | Revenue Growth: | -98.89% |
| Revenue Growth (this year): | 27.18% | Revenue Growth (next year): | N/A |
Latest Barinthus Biotherapeutics plc News
BRNS Breaking Stock News: Dive into BRNS Ticker-Specific Updates for Smart Investing
GlobeNewswire
24 days ago
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
GOBankingRates
a month ago
5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
AFP
a month ago
Bumrah delivers as India beat Pakistan in low-scoring thriller
AFP
a month ago
Italy beat Bosnia in final Euros warm-up
Bloomberg
a month ago
Macron Calls French Legislative Election After Far-Right Surge
AFP
a month ago
Trump loyalists proud to support 'felon' at Las Vegas rally
Business Insider
a month ago
US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
Insider Monkey
a month ago
The Best Woody Perfume For Women
Share on Social Networks:
Disclaimer
The information presented on this page, "BRNS Barinthus Biotherapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.